instruction
stringlengths 33
156
| input
float64 | output
stringlengths 120
1.97k
|
---|---|---|
Does Abatacept and Tasimelteon interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Tasimelteon can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Tazarotene interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates. In short, The metabolism of Tazarotene can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Tazemetostat interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Tazemetostat can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Tegaserod interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Tegaserod can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Telithromycin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Telithromycin can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Temozolomide interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Temozolomide is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Temsirolimus interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Temsirolimus can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Teniposide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates with a narrow therapeutic index. In short, The metabolism of Teniposide can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Tenofovir alafenamide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Tenofovir alafenamide can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Tenoxicam interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Tenoxicam can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Teprotumumab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Teprotumumab, and the severity of the interaction is major. |
Does Abatacept and Terbinafine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Terbinafine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Terfenadine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Terfenadine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Teriflunomide interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Teriflunomide, and the severity of the interaction is major. |
Does Abatacept and Testosterone cypionate interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Testosterone cypionate can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Testosterone enanthate interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Testosterone enanthate can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Testosterone interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Testosterone can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Tetrabenazine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Tetrabenazine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Thalidomide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Thalidomide can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Theophylline interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Theophylline can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Thiopental interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates with a narrow therapeutic index. In short, The metabolism of Thiopental can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Thioridazine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Thioridazine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Thiotepa interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Thiotepa can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Thiothixene interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Thiothixene can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Ticagrelor interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Ticagrelor can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Tick-borne encephalitis vaccine (whole virus, inactivated) interact? | null | Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Ticlopidine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Ticlopidine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Timolol interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Timolol can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Tioguanine interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Tioguanine is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Tiotropium interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Tiotropium can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Tipranavir interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Tipranavir can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Tixocortol interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Tixocortol, and the severity of the interaction is major. |
Does Abatacept and Tizanidine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Tizanidine can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Tocilizumab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Tocilizumab, and the severity of the interaction is major. |
Does Abatacept and Tofacitinib interact? | null | When combined with biologic drugs such as abatacept, tofacitinib may cause enhanced toxic effects such as an increased risk of serious systemic and local infection , . In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Tofacitinib, and the severity of the interaction is major. |
Does Abatacept and Tolazamide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Tolazamide can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Tolbutamide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Tolbutamide can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Tolterodine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Tolterodine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Tolvaptan interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Tolvaptan can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Topotecan interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Topotecan is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Torasemide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Torasemide can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Trabectedin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates with a narrow therapeutic index. In short, The metabolism of Trabectedin can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Tramadol interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Tramadol can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Trastuzumab emtansine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Trastuzumab emtansine can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Trastuzumab interact? | null | While trastuzumab treatment itself can cause neutropenia, its co-administration with other immunosuppressive agents has been shown to result in synergistic neutropenic effects. In randomized controlled clinical trials, patients receiving trastuzumab in combination with myelosuppressive chemotherapy had higher rates of moderate to severe neutropenia and febrile neutropenia compared to those receiving chemotherapy alone. The pathophysiologic basis for this exacerbation of neutropenia has not been determined. In short, The risk or severity of neutropenia can be increased when Trastuzumab is combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Trazodone interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Trazodone can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Treprostinil interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Treprostinil can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Tretinoin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Tretinoin can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Triamcinolone interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Triamcinolone can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Triamterene interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Triamterene can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Triazolam interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Triazolam can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Triclabendazole interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Triclabendazole can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Trifluoperazine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Trifluoperazine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Trifluridine interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Trifluridine is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Trimethoprim interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Trimethoprim can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Trimipramine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates with a narrow therapeutic index. In short, The metabolism of Trimipramine can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Tucatinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates. In short, The metabolism of Tucatinib can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Typhoid Vaccine Live interact? | null | In most cases, the coadministration of live vaccines and immunosuppressive agents is contraindicated due to the risk of uncontrolled replication of the virus and subsequent infection. Drugs capable of causing clinically significant immunosuppression include chemotherapeutic agents (e.g. alkylating agents, antimetabolites), high-dose corticosteroids, and immune mediators/modulators (e.g. TNF-alpha inhibitors). In short, The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Typhoid vaccine interact? | null | Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Typhoid Vi polysaccharide vaccine interact? | null | Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Ublituximab interact? | null | Prescribing information for Briumvi (ublituximab-xiiy) states that its co-administration with immunosuppressants (e.g. immunosuppressive doses of corticosteroids) may increase the risk of infection. Ublituximab, a B-cell depleting agent, is itself an immunosuppressive medication - the co-administration of ublituximab with agents exerting a similar effect may therefore result in additive immunosuppression and a subsequent increase in the risk of developing an infection. In short, The risk or severity of infection can be increased when Ublituximab is combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Udenafil interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Udenafil can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Umeclidinium interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Umeclidinium can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Upadacitinib interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Upadacitinib, and the severity of the interaction is major. |
Does Abatacept and Valbenazine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Valbenazine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Valdecoxib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Valdecoxib can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Valproic acid interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2A6 substrates. In short, The metabolism of Valproic acid can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Valsartan interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Valsartan can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Vandetanib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Vandetanib can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Vardenafil interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Vardenafil can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Varicella zoster vaccine (liveattenuated) interact? | null | In most cases, the coadministration of live vaccines and immunosuppressive agents is contraindicated due to the risk of uncontrolled replication of the virus and subsequent infection. Drugs capable of causing clinically significant immunosuppression include chemotherapeutic agents (e.g. alkylating agents, antimetabolites), high-dose corticosteroids, and immune mediators/modulators (e.g. TNF-alpha inhibitors). In short, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Varicella zoster vaccine (recombinant) interact? | null | Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Vedolizumab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Vedolizumab, and the severity of the interaction is major. |
Does Abatacept and Vemurafenib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Vemurafenib can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Venetoclax interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Venetoclax can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Venlafaxine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Venlafaxine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Verapamil interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Verapamil can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Vernakalant interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Vernakalant can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Vibrio cholerae CVD 103-HgR strain live antigen interact? | null | High doses of immunosuppressive agents, such as antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids in combination with the cholera vaccine may reduce the immune response to the vaccine. In short, The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Abatacept, and the severity of the interaction is minor. |
Does Abatacept and Vilanterol interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Vilanterol, and the severity of the interaction is major. |
Does Abatacept and Vilazodone interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Vilazodone can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Vinblastine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Vinblastine can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Vincristine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Vincristine can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Vindesine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Vindesine can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Vinflunine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Vinflunine can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Vinorelbine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Vinorelbine can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Voclosporin interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Voclosporin, and the severity of the interaction is major. |
Does Abatacept and Vonoprazan interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Vonoprazan can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Vorapaxar interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Vorapaxar can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Voriconazole interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Voriconazole can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Vorinostat interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Vorinostat, and the severity of the interaction is major. |
Does Abatacept and Vortioxetine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2A6 substrates. In short, The metabolism of Vortioxetine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Voxelotor interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Voxelotor can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Warfarin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Warfarin can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Yellow fever vaccine interact? | null | In most cases, the coadministration of live vaccines and immunosuppressive agents is contraindicated due to the risk of uncontrolled replication of the virus and subsequent infection. Drugs capable of causing clinically significant immunosuppression include chemotherapeutic agents (e.g. alkylating agents, antimetabolites), high-dose corticosteroids, and immune mediators/modulators (e.g. TNF-alpha inhibitors). In short, The risk or severity of infection can be increased when Yellow fever vaccine is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Yohimbine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Yohimbine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Zafirlukast interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Zafirlukast can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Zaleplon interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Zaleplon can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Zanubrutinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates with a narrow therapeutic index. In short, The metabolism of Zanubrutinib can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Zidovudine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2A6 substrates. In short, The metabolism of Zidovudine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |